Assessment Of The Efficacy And Safety Of Pharmacotherapeutic Agents In The Management Of Allergic Rhinitis

Abstract

Allergic rhinitis (AR) is a prevalent condition affecting 30% of the Indian population, with significant morbidity, socioeconomic impact, and under-optimized treatment. Despite various therapies, the management of AR remains suboptimal due to several barriers.
To evaluate the efficacy and safety of commonly prescribed pharmacotherapeutic agents, including oral/intranasal antihistamines, intranasal corticosteroids, and immunotherapies (subcutaneous and sublingual), in AR management. A 12-month prospective observational study was conducted at a tertiary care hospital in India. Patients with a clinical diagnosis of AR were recruited and treated as per their physician’s prescriptions. Efficacy was assessed using the Total Nasal Symptom Score (TNSS) and Rhino conjunctivitis Quality of Life Questionnaire (RQLQ). Safety data and adverse events were also analyzed. Among 230 participants, intranasal corticosteroids (INCS) showed the most significant symptom reduction (71%) and quality of life improvement (61%), followed by subcutaneous (66%) and sublingual (63%) immunotherapy. Adverse events were minimal, with SCIT associated with localized injection reactions. INCS was found as the most effective therapy for AR management, followed by immunotherapies. Tailored treatments based on symptom severity and patient preferences are crucial for optimal outcomes.